NCT01772771

Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

Recruiting now Last updated 3 March 2026

What this trial tests

trial testing Biospecimen Collection in Glioma in 12,000 participants. Currently enrolling.

Timeline

1 March 2012

Primary endpoint
1 March 2032

1 March 2033

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	12,000
Start date	1 March 2012
Primary completion	1 March 2032
Estimated completion	1 March 2033
Sites	1 location across United States

Drugs / interventions tested

• Biospecimen Collection — full drug profile →
• Genetic Testing
• Medical Chart Review

Conditions studied

• Glioma — all drugs for Glioma →
• Hematopoietic and Lymphoid Cell Neoplasm — all drugs for Hematopoietic and Lymphoid Cell Neoplasm →
• Malignant Solid Neoplasm — all drugs for Malignant Solid Neoplasm →
• Melanoma — all drugs for Melanoma →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Eligibility, any sex, with Glioma or Hematopoietic and Lymphoid Cell Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study performs standardized testing of tumor tissue samples to learn which genes are mutated (have changed) in order to provide personalized cancer therapy options to cancer patients at MD Anderson. This may help doctors use testing information on tumors to identify clinical trials that may be most relevant to patients. Researchers may also use the information learned from this study to develop a database of the different kinds of mutations in cancer-related genes.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
   Meric-Bernstam F, Brusco L, Shaw K, Horombe C, et al · · 2015 · cited 327× · PMID 26014291 · DOI 10.1200/jco.2014.60.4165
2. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.
   Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, et al · · 2016 · cited 138× · PMID 26787237 · DOI 10.1093/annonc/mdw018
3. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer.
   Pairawan S, Hess KR, Janku F, Sanchez NS, et al · · 2020 · cited 65× · PMID 31852833 · DOI 10.1158/1078-0432.ccr-19-0306
4. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA.
   Kaseb AO, Sánchez NS, Sen S, Kelley RK, et al · · 2019 · cited 64× · PMID 31363003 · DOI 10.1158/1078-0432.ccr-18-3341
5. Survival Outcomes by <i>TP53</i> Mutation Status in Metastatic Breast Cancer.
   Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, et al · · 2018 · cited 63× · PMID 30035249 · DOI 10.1200/po.17.00245
6. Molecular spectrum of <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i>, <i>PIK3CA</i>, <i>TP53</i>, and <i>APC</i> somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.
   Al-Shamsi HO, Jones J, Fahmawi Y, Dahbour I, et al · · 2016 · cited 51× · PMID 28078112 · DOI 10.21037/jgo.2016.11.02
7. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics.
   Cachia D, Kamiya-Matsuoka C, Mandel JJ, Olar A, et al · · 2015 · cited 46× · PMID 26354773 · DOI 10.1007/s11060-015-1930-y
8. <i>RAC1</i> Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient.
   Bagheri-Yarmand R, Busaidy NL, McBeath E, Danysh BP, et al · · 2021 · cited 29× · PMID 34638434 · DOI 10.3390/cancers13194950